Lars Beckman
Umea, AC, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial.
Journal: The Lancet. Oncology
Published: July 28, 2025
Symptom burden among men treated for castration-resistant prostate cancer: a longitudinal study.
Journal: BMJ supportive & palliative care
Published: June 25, 2024
Symptoms and quality of life among men starting treatment for metastatic castration-resistant prostate cancer - a prospective multicenter study.
Journal: BMC palliative care
Published: April 19, 2023
A randomized controlled pilot study assessing feasibility and safety of a wilderness program for childhood, adolescent, and young adult cancer survivors: the WAYA study.
Journal: BMC public health
Published: December 08, 2022
Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study.
Journal: Radiation oncology (London, England)
Published: November 15, 2022
Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer-A qualitative study.
Journal: European journal of cancer care
Published: September 23, 2021
Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost-utility analysis alongside a randomized HYPO-RT-PC trial.
Journal: The European journal of health economics : HEPAC : health economics in prevention and care
Published: August 27, 2021
Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy.
Journal: Physics and imaging in radiation oncology
Published: June 13, 2020
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Journal: The Lancet. Oncology
Published: May 31, 2020
Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 20, 2019
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Journal: Lancet (London, England)
Published: February 28, 2019
Inter-fraction movements of the prostate and pelvic lymph nodes during IGRT.
Journal: Journal of radiation oncology
Published: January 29, 2018
Showing 1-12 of 12
Last Updated: 09/26/2026